Applied Clinical Trials
Five key pieces to a lasting and successful sponsor/CRO relationship.
Forging a sponsor/CRO relationship that will last—and that will benefit both parties—requires up-front planning, open communication, and feedback.
Medpace's model for success has five key components, and these core elements have evolved over time and strengthened its partnership with sponsors.
Five-step model
Define expectations regarding the quality of deliverables.
The sponsor and CRO should jointly identify key aspects of the relationship. This should include the qualifications and minimal training requirements of the CRO personnel and the SOPs that will be used to run the study. It describes quality management plans and it defines the study plans, including the communication plan, the recruitment and retention plan, risk mitigation plans, and other strategic documents used to manage the program. It defines the expectations regarding audit readiness on the site and CRO level.
Define governance details.
Define the purpose of the alliance and outline the expectations for each committee involved in the governance relationship and key performance indicators and metrics that are going to be measured.
Outline a multi-tiered oversight and management structure. There are often three levels of support:
Generate periodic summary reports.
Summarize the key milestones that have been achieved, upcoming deliverables, and the risks that are inherent in the program at that point in time. This is not a litany of the risks that have been observed throughout the course of the project, but those that are intractable or particularly critical, and they are ranked by the detail of their severity or urgency.
Report on financial metrics.
Can include standardized quarterly reporting, task-based revenue accrual, and can give an indication of pass-through and escrow costs incurred versus what was budgeted up to that point in time, detailed invoicing history, and a listing of change in scopes as they have occurred by project and across the program.
Measure success.
Key performance indicators should be defined so that the success of the collaborative team can be measured. As examples, consider:
Most important benefits for a sponsor when entering into a strategic partnership
Partnership success story
Other benefits include developing mutually agreeable processes and applying lessons learned from previous collaborations. Once a relationship is established, both organizations better understand the preferred method of handling certain situations and how the CRO can best operate within the sponsor's team structure. Lessons learned can be applied to other projects in the program which eliminates some of the inefficiencies that might be inherent each time a relationship is started with a new CRO. In conclusion, developing a strong sponsor/CRO relationship requires time, commitment, planning, and expertise. For this up-front investment, the rewards are many.
Debbie Elliott, PhD, is Senior Director of Clinical Operations at Medpace, 5375 Medpace Way, Cincinnati, OH.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.